SG11202013176VA - Compositions and methods for treating inflammasome related diseases or conditions - Google Patents

Compositions and methods for treating inflammasome related diseases or conditions

Info

Publication number
SG11202013176VA
SG11202013176VA SG11202013176VA SG11202013176VA SG11202013176VA SG 11202013176V A SG11202013176V A SG 11202013176VA SG 11202013176V A SG11202013176V A SG 11202013176VA SG 11202013176V A SG11202013176V A SG 11202013176VA SG 11202013176V A SG11202013176V A SG 11202013176VA
Authority
SG
Singapore
Prior art keywords
compositions
conditions
methods
related diseases
inflammasome related
Prior art date
Application number
SG11202013176VA
Inventor
Robert W Keane
W Dalton Dietrich
Rivero Vaccari Juan Pablo De
Helen M Bramlett
Roberta Brambilla
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/026,482 external-priority patent/US10703811B2/en
Application filed by Univ Miami filed Critical Univ Miami
Publication of SG11202013176VA publication Critical patent/SG11202013176VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11202013176VA 2018-07-03 2019-07-03 Compositions and methods for treating inflammasome related diseases or conditions SG11202013176VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/026,482 US10703811B2 (en) 2016-12-29 2018-07-03 Methods and compositions for treating multiple sclerosis
PCT/US2019/040635 WO2020010273A1 (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammasome related diseases or conditions

Publications (1)

Publication Number Publication Date
SG11202013176VA true SG11202013176VA (en) 2021-01-28

Family

ID=78823964

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202013176VA SG11202013176VA (en) 2018-07-03 2019-07-03 Compositions and methods for treating inflammasome related diseases or conditions

Country Status (16)

Country Link
US (1) US20210284723A1 (en)
EP (1) EP3818081A4 (en)
JP (1) JP2021528092A (en)
KR (1) KR20210071944A (en)
CN (1) CN113316588A (en)
AU (1) AU2019297515A1 (en)
BR (1) BR112020026798A2 (en)
CA (1) CA3105129A1 (en)
CL (1) CL2020003447A1 (en)
CO (1) CO2021001172A2 (en)
IL (1) IL279851A (en)
MX (1) MX2021000142A (en)
PH (1) PH12020552286A1 (en)
SG (1) SG11202013176VA (en)
WO (1) WO2020010273A1 (en)
ZA (1) ZA202100703B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007916A (en) 2016-12-29 2019-12-05 Univ Miami Method for modulating inflammasome activity and inflammation in the lung.
US11840565B2 (en) 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation
CA3176521A1 (en) * 2020-04-27 2021-11-04 University Of Miami Compositions and methods for treating inflammasome related diseases or conditions
AR127692A1 (en) * 2021-11-16 2024-02-21 Ac Immune Sa ANTI-ASC ANTIBODIES FOR USE IN ANTI-INFLAMMATORY TREATMENTS
WO2024055015A1 (en) * 2022-09-09 2024-03-14 University Of Miami Inflammasome antibody compositon and method for treating neurologic disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
JP4496214B2 (en) * 2004-05-17 2010-07-07 電気化学工業株式会社 Polyvinyl chloride fiber, method for producing the same, and artificial hair
KR20070094890A (en) * 2004-10-25 2007-09-27 머크 앤드 캄파니 인코포레이티드 Anti-addl antibodies and uses thereof
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2008106116A2 (en) * 2007-02-27 2008-09-04 Genentech, Inc. Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
US8685400B2 (en) * 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
US20100150938A1 (en) * 2008-07-03 2010-06-17 University Of Massachusetts Methods and compositions for reducing inflammation and treating inflammatory disorders
SG185465A1 (en) * 2010-05-14 2012-12-28 Amgen Inc High concentration antibody formulations
CA2826820A1 (en) * 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Asc as marker for chronic obstructive pulmonary disease (copd)
US20140314746A1 (en) * 2013-03-13 2014-10-23 Philadelphia Health And Education Corporation, d/b/a Drexel University College of Medicine Methods for treating or preventing fibrosis in subjects afflicted with scleroderma
JP6359013B2 (en) * 2013-07-29 2018-07-18 国立大学法人 鹿児島大学 Inhibitor of apoptosis-related spec-like card protein containing 1,5-D-anhydrofructose
KR101948048B1 (en) * 2016-12-08 2019-02-14 한양대학교 에리카산학협력단 Pharmaceutical composition for preventing or treating tuberculosis comprising Toxoplasma gondii-GRA7 recombinant protein as an active ingredient
MX2019007916A (en) * 2016-12-29 2019-12-05 Univ Miami Method for modulating inflammasome activity and inflammation in the lung.
US11840565B2 (en) * 2016-12-29 2023-12-12 University Of Miami Methods and compositions for treating virus-associated inflammation

Also Published As

Publication number Publication date
JP2021528092A (en) 2021-10-21
US20210284723A1 (en) 2021-09-16
BR112020026798A2 (en) 2021-03-30
CO2021001172A2 (en) 2021-07-09
EP3818081A4 (en) 2022-06-22
CN113316588A (en) 2021-08-27
CL2020003447A1 (en) 2021-07-30
MX2021000142A (en) 2021-05-12
ZA202100703B (en) 2022-08-31
WO2020010273A1 (en) 2020-01-09
CA3105129A1 (en) 2020-01-09
IL279851A (en) 2021-03-01
KR20210071944A (en) 2021-06-16
AU2019297515A1 (en) 2021-02-25
PH12020552286A1 (en) 2021-06-21
EP3818081A1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
IL298690B1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
IL273959A (en) Methods and compositions for the treatment of rare diseases
EP3826666A4 (en) Compositions and methods for treating nrp2-associated diseases
EP3634424A4 (en) Compositions and methods for preventing or treating muscle conditions
AU2018297285A1 (en) Compositions and methods for treating or preventing endocrine FGF-linked diseases
ZA202100703B (en) Compositions and methods for treating inflammasome related diseases or conditions
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL272937A (en) Compositions and methods for the treatment of fibrotic diseases
EP3609525A4 (en) Compositions and methods for treating or preventing gut permeability-related disorders
IL275767A (en) Compositions and methods for treating metabolic diseases
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
EP3687524A4 (en) Compositions and methods for treating ophthalmic conditions
IL269743A (en) Methods and compositions for treating retina-associated disease using ccr3-inhibitors
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
EP3768095A4 (en) Compositions and methods for treating diarrheal diseases
EP3393460A4 (en) Compositions and methods of treatment for mvid and related diseases
PL3810128T3 (en) Compositions for treating and/or preventing protein-aggregation diseases
IL261779A (en) Compositions for the treatment and prevention of hoof and claw diseases
EP3672583A4 (en) Compositions and methods for treating neurodegenerative diseases
EP3310338A4 (en) Compositions and methods for treating inflammatory disease or conditions
EP3585411A4 (en) Il-22bp compositions and method for the treatment of disease therewith
EP3661492A4 (en) Methods and compositions for treating neurological conditions
EP3496696A4 (en) Compositions and methods for treating disease
EP3724230A4 (en) Compositions and methods for treating or preventing endocrine fgf23-linked diseases